Home › Funds › Redmile Group, LLC › CLDX

Redmile Group, LLC position in CLDX

CELLDEX THERAPEUTICS INC NEW · Health Care

Redmile Group, LLC reported holding 433,921 shares of CLDX (CELLDEX THERAPEUTICS INC NEW) in its Q2 2026 13F filing — a position valued at US$16.1M, representing 1.08% of its reported portfolio and ranking #19 among its reported holdings. Redmile Group, LLC has disclosed CLDX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)433.92K sh
Reported value held$16.15M
Portfolio Weight1.08%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Redmile Group, LLC's CLDX position evolved

Redmile Group, LLC first disclosed a stake in CLDX in Q3 2023 at 1,635,938 shares (US$45.0M). Across 12 filings, Redmile Group, LLC increased the stake 1 time(s), trimmed it 10 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 433,921 shares valued at US$16.1M — an increase of 172,413 shares quarter over quarter.. Notable position changes include a 39% trim in Q4 2023 (shares rose 6% over the following quarter), a 42% trim in Q2 2025 (shares rose 27% over the following quarter), a 66% increase in Q2 2026 (shares fell 13% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.64M $45.02M New
Q4 2023 993.80K $39.41M Reduce
Q1 2024 896.45K $37.62M Reduce
Q2 2024 718.72K $26.60M Reduce
Q3 2024 657.17K $22.34M Reduce
Q4 2024 615.77K $15.56M Reduce
Q1 2025 590.17K $10.71M Reduce
Q2 2025 343.03K $6.98M Reduce
Q3 2025 327.01K $8.46M Reduce
Q4 2025 283.31K $7.69M Reduce
Q1 2026 261.51K $8.30M Reduce
Q2 2026 433.92K $16.15M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CLDX and 13F data

CLDX (CELLDEX THERAPEUTICS INC NEW) is a Health Care company. 44 other funds we track also report a position in CLDX — the largest reported positions include Kynam Capital Management, LP (US$198.1M), Deep Track Capital, LP (US$109.4M), Logos Global Management LP (US$78.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CLDX

All CLDX fund holders →

FAQ

How long has Redmile Group, LLC held CLDX?

Redmile Group, LLC has disclosed CLDX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Redmile Group, LLC's current position in CLDX?

As of Q2 2026, Redmile Group, LLC holds 433.92K shares of CLDX (CELLDEX THERAPEUTICS INC NEW), valued at $16.15M, representing 1.08% of its reported portfolio and ranking #19.

Has Redmile Group, LLC been buying or selling CLDX?

In the latest 13F filing (Q2 2026), Redmile Group, LLC increased its position in CLDX.

Which other funds hold CLDX?

Other major institutional holders of CLDX include Kynam Capital Management, LP, Deep Track Capital, LP, Logos Global Management LP, among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.